ZA201904861B - Method for modulating inflammasome activity and inflammation in the lung - Google Patents

Method for modulating inflammasome activity and inflammation in the lung

Info

Publication number
ZA201904861B
ZA201904861B ZA2019/04861A ZA201904861A ZA201904861B ZA 201904861 B ZA201904861 B ZA 201904861B ZA 2019/04861 A ZA2019/04861 A ZA 2019/04861A ZA 201904861 A ZA201904861 A ZA 201904861A ZA 201904861 B ZA201904861 B ZA 201904861B
Authority
ZA
South Africa
Prior art keywords
inflammation
modulating
lung
inflammasome activity
inflammasome
Prior art date
Application number
ZA2019/04861A
Other languages
English (en)
Inventor
Keane Robert
Dietrich Dalton
Kerr Nadine
Wu Shu
Pablo De Rivero Vaccari Juan
Original Assignee
Univ Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Miami filed Critical Univ Miami
Publication of ZA201904861B publication Critical patent/ZA201904861B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2019/04861A 2016-12-29 2019-07-24 Method for modulating inflammasome activity and inflammation in the lung ZA201904861B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662440180P 2016-12-29 2016-12-29
PCT/US2017/068713 WO2018126009A1 (en) 2016-12-29 2017-12-28 Method for modulating inflammasome activity and inflammation in the lung

Publications (1)

Publication Number Publication Date
ZA201904861B true ZA201904861B (en) 2024-11-27

Family

ID=62710025

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2019/04861A ZA201904861B (en) 2016-12-29 2019-07-24 Method for modulating inflammasome activity and inflammation in the lung

Country Status (16)

Country Link
US (5) US20190336598A1 (enExample)
EP (2) EP3562506A4 (enExample)
JP (3) JP2020503345A (enExample)
KR (1) KR20200013630A (enExample)
CN (1) CN110461356A (enExample)
AU (1) AU2017386550A1 (enExample)
BR (1) BR112019013463A2 (enExample)
CA (2) CA3048864A1 (enExample)
CO (1) CO2019008087A2 (enExample)
IL (1) IL267685A (enExample)
MX (1) MX2019007916A (enExample)
PH (1) PH12019501549A1 (enExample)
RU (1) RU2019123160A (enExample)
SG (1) SG10202106385XA (enExample)
WO (2) WO2018126009A1 (enExample)
ZA (1) ZA201904861B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021222263A2 (en) * 2020-04-27 2021-11-04 University Of Miami Compositions and methods for treating inflammasome related diseases or conditions
US11840565B2 (en) 2016-12-29 2023-12-12 University Of Miami Methods and compositions for treating virus-associated inflammation
WO2018126009A1 (en) 2016-12-29 2018-07-05 University Of Miami Method for modulating inflammasome activity and inflammation in the lung
SG11202013176VA (en) * 2018-07-03 2021-01-28 Univ Miami Compositions and methods for treating inflammasome related diseases or conditions
EP3938781B1 (en) * 2019-03-13 2025-12-10 Fundación para la Formación e Investigación Sanitarias de la Región De Murcia (FFIS) In vitro
WO2021097084A1 (en) * 2019-11-12 2021-05-20 The Uab Research Foundation Methods for treating immunosuppression and diseases associated with immunosuppression
CN111363847B (zh) * 2020-02-12 2021-06-29 广州微远医疗器械有限公司 基于CRISPR技术的2019-nCoV快速检测引物组及其用途
CN113278730B (zh) * 2020-02-20 2022-03-25 中元汇吉生物技术股份有限公司 一种新型冠状病毒检测试剂盒、用途及其使用方法
US20230172933A1 (en) * 2020-03-19 2023-06-08 Nanyang Technological University Use of a compound or composition comprising an inhibitor of nlrp1 inflammasome activation for the treatment of human airway inflammation
CN111289745A (zh) * 2020-03-25 2020-06-16 中山生物工程有限公司 新型冠状病毒IgM抗体酶联免疫检测试剂盒及其检测方法
KR102658146B1 (ko) * 2020-03-26 2024-04-18 경북대학교 산학협력단 Pannexin3을 포함하는 근육 손상 진단용 바이오마커 조성물 및 이를 이용한 진단방법
CN111529707B (zh) * 2020-04-29 2021-04-23 威海市立医院 Gsdmd抑制剂在制备治疗幽门螺杆菌感染的药物中的应用
CN111777684A (zh) * 2020-06-09 2020-10-16 重庆君同生物技术有限公司 冠状病毒串联表位蛋白所诱导抗体的制备方法及其应用
IL299793A (en) * 2020-07-09 2023-03-01 Remedy Cell Ltd Methods for treating acute respiratory distress syndrome and cytokine storm
KR102582417B1 (ko) * 2020-11-06 2023-09-26 한국과학기술원 인플라마솜 어댑터 단백질(asc)의 중합체화 도메인에 결합하는 신규한 폴리펩타이드 및 이의 용도
AU2022211971A1 (en) 2021-01-29 2023-08-10 Illimis Therapeutics, Inc. Fusion molecule having non-inflammatory phagocytosis inducing activity
CN113109569B (zh) * 2021-03-05 2022-08-19 李朴 Gsdmd作为生物标志物在胸腔积液相关疾病鉴别诊断及疗效评估上的用途
KR102673132B1 (ko) * 2021-04-20 2024-06-12 아주대학교산학협력단 염증성 질환 치료를 위한 nlrp3 인플라마좀 억제 펩타이드
EP4337676A1 (en) 2021-05-10 2024-03-20 Entrada Therapeutics, Inc. Antigen-binding and antigen degradation constructs
CN118119644A (zh) * 2021-08-25 2024-05-31 R.P.谢勒技术有限责任公司 具有人源化框架区的抗体
CN115819548B (zh) * 2021-11-16 2023-09-01 北京美德泰康生物科技有限公司 一种检测炎症相关疾病的标志物和方法
WO2024006457A1 (en) * 2022-06-29 2024-01-04 University Of South Florida Method of treating long-covid induced neurologic diseases
WO2024114906A1 (en) 2022-11-30 2024-06-06 Mabylon Ag Antibodies against apoptosis-associated speck-like protein containing a card (asc) and uses thereof
WO2024248287A1 (ko) * 2023-06-01 2024-12-05 한양대학교 에리카산학협력단 결핵균 유래 폴리펩타이드를 포함하는 염증성 질환 치료용 약학 조성물
WO2025081130A1 (en) * 2023-10-12 2025-04-17 University Of Miami Use of anti-asc antibody in the treating of ocular disorders

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
CA2565063A1 (en) 2004-04-29 2005-11-24 Otsuka Pharmaceutical Co., Ltd. Glycoprotein vi antibodies and method thereof
US7780963B2 (en) 2004-10-25 2010-08-24 Merck & Co., Inc. Anti-ADDL antibodies and uses thereof
TW200636064A (en) 2004-10-28 2006-10-16 Centocor Inc Anti-respiratory syncytial virus antibodies, antigens and uses thereof
CA2679399A1 (en) 2007-02-27 2008-09-04 Genetech, Inc. Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
WO2009014863A2 (en) * 2007-06-29 2009-01-29 Thomas Jefferson University Asc and pyrin-asc pyroptosomes and uses thereof
US8685400B2 (en) * 2007-07-30 2014-04-01 University Of Miami Modulating inflammasome activity and inflammation in the central nervous system
US20100150938A1 (en) * 2008-07-03 2010-06-17 University Of Massachusetts Methods and compositions for reducing inflammation and treating inflammatory disorders
AU2010294225A1 (en) * 2009-09-11 2012-04-05 Protaffin Biotechnologie Ag Composition for treatment of CXCL8-mediated lung inflammation
SMT202000095T1 (it) 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
IT1406201B1 (it) 2010-12-10 2014-02-14 Univ Degli Studi Trieste Biomarcatori per la diagnosi della sclerosi multipla
CA2826820A1 (en) 2011-03-11 2012-09-20 F. Hoffmann-La Roche Ag Asc as marker for chronic obstructive pulmonary disease (copd)
WO2013119673A1 (en) 2012-02-06 2013-08-15 University Of Miami Innate immune proteins as biomarkers for cns injury
TWI480044B (zh) 2012-03-16 2015-04-11 Taichung Veterans General Hospital A high molecular weight heparin or low molecular weight heparin for the preparation of a composition for at least two consecutive days of administration to improve the allergic constitution
US20140314746A1 (en) * 2013-03-13 2014-10-23 Philadelphia Health And Education Corporation, d/b/a Drexel University College of Medicine Methods for treating or preventing fibrosis in subjects afflicted with scleroderma
KR20160005044A (ko) * 2013-05-17 2016-01-13 제넨테크, 인크. 염증성 장 질환의 진단 및 치료 방법
WO2015016178A1 (ja) * 2013-07-29 2015-02-05 国立大学法人鹿児島大学 １，５－ｄ－アンヒドロフルクトースを含むアポトーシス関連スペック様カード蛋白質の機能阻害薬
NZ722927A (en) * 2014-01-10 2022-07-29 Avalyn Pharma Inc Aerosol pirfenidone and pyridone analog compounds and uses thereof
US10143709B2 (en) * 2014-05-06 2018-12-04 Indiana University Research And Technology Corporation Use of ASC and ASC-CM to treat ARDS, SARS, and MERS
WO2016028699A2 (en) 2014-08-18 2016-02-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Biomarkers for diagnosis and management of neuro-immunological diseases
US20160263183A1 (en) 2015-03-10 2016-09-15 Brown University Methods for treating lung disease
EP3294752B1 (en) * 2015-05-12 2020-11-04 The Regents of the University of California Peptide treatment for inflammation and fibrosis
TWI743047B (zh) 2015-08-17 2021-10-21 安成生物科技股份有限公司 使用雙醋瑞因或其類似物抑制asc表現、nlrp3表現、以及/或nlrp3發炎體複合物的形成之方法
KR101948048B1 (ko) 2016-12-08 2019-02-14 한양대학교 에리카산학협력단 톡소포자충 ｇｒａ７ 항원 유래 재조합 단백질을 유효성분으로 포함하는 결핵 예방 또는 치료용 약학 조성물
WO2018126009A1 (en) 2016-12-29 2018-07-05 University Of Miami Method for modulating inflammasome activity and inflammation in the lung
KR20200088299A (ko) 2017-09-20 2020-07-22 더 유니버시티 오브 마이애미 신경학적 장애의 바이오마커로서 인플라마솜 단백질의 검출 방법
SG11202013176VA (en) 2018-07-03 2021-01-28 Univ Miami Compositions and methods for treating inflammasome related diseases or conditions

Also Published As

Publication number Publication date
CA3176518A1 (en) 2021-10-28
MX2019007916A (es) 2019-12-05
US20200308262A1 (en) 2020-10-01
WO2018126009A1 (en) 2018-07-05
WO2021217004A2 (en) 2021-10-28
EP3562506A4 (en) 2021-01-06
US20210324065A1 (en) 2021-10-21
CA3048864A1 (en) 2018-07-05
WO2021217004A3 (en) 2021-12-16
RU2019123160A (ru) 2021-01-29
SG10202106385XA (en) 2021-07-29
US20190336598A1 (en) 2019-11-07
EP4139348A4 (en) 2024-08-14
CO2019008087A2 (es) 2019-10-21
JP2023515271A (ja) 2023-04-12
US10703811B2 (en) 2020-07-07
US20200347124A1 (en) 2020-11-05
BR112019013463A2 (pt) 2020-01-07
EP3562506A1 (en) 2019-11-06
US10961306B2 (en) 2021-03-30
CN110461356A (zh) 2019-11-15
KR20200013630A (ko) 2020-02-07
US11174307B2 (en) 2021-11-16
IL267685A (en) 2019-08-29
EP4139348A2 (en) 2023-03-01
JP2023016835A (ja) 2023-02-02
JP2020503345A (ja) 2020-01-30
PH12019501549A1 (en) 2020-02-24
RU2019123160A3 (enExample) 2021-01-29
US20190002550A1 (en) 2019-01-03
AU2017386550A1 (en) 2019-08-08

Similar Documents

Publication Publication Date Title
ZA201904861B (en) Method for modulating inflammasome activity and inflammation in the lung
PH12016501668A1 (en) Compositions and methods for the reduction or prevention of hepatic steatosis
ZA202007007B (en) Mcl-1 inhibitors
ZA202201437B (en) Compositions and methods for treating inflammasome related diseases or conditions
MY185614A (en) Use of myostatin inhibitors and combination therapies
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX384792B (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
MX2022007472A (es) Uso de plinabulina en combinacion con inhibidores de punto de control inmunitario.
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
PH12015501964B1 (en) Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
MX2017005457A (es) Metodos y compuestos agonistas de gip.
AU2016261707A8 (en) Use of cannabis to treat fibromyalgia, methods and compositions thereof
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
MX2022014634A (es) Metodos para la administracion linfatica de agentes activos.
NZ702415A (en) Methods for treating neutropenia using retinoid agonists
GB2548277A (en) Antibiofilm compositions
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
BR112018009609A8 (pt) composições dentifrícias com absorção melhorada de fluoreto
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
WO2017040407A8 (en) Compositions and methods for the reduction or prevention of non-alcoholic steatohepatitis (nash)
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.
BR112017000157A2 (pt) composições bucais anticálculo
AR092691A1 (es) Composicion farmaceutica que comprende rebamipida
MX2019010913A (es) Analogos de deutetrabenazina, su preparacion y uso.
BR112016014099A2 (pt) método de tratamento de feridas